"Relapsed or refractory" and "prior lines of therapy" are the two phrases that determine almost all CAR-T eligibility decisions. Here is what they actually mean.

"Relapsed" vs. "refractory" — not the same thing

Relapsed means your cancer responded to treatment and then came back. Refractory means it never fully responded in the first place. Most approved CAR-T indications require one or the other, following specific standard treatment.

What counts as a "prior line of therapy"

Each approved CAR-T product specifies a minimum number of prior treatment regimens — for example, multiple myeloma products typically require at least three prior lines, including a proteasome inhibitor and an immunomodulatory drug, while some lymphoma products apply from the second line onward. A "line" generally means a distinct treatment regimen, not each individual cycle of the same regimen; your reviewing physician will map your specific history against the product's criteria.

Factors beyond diagnosis and treatment history

  • Organ function — heart, lung, kidney and liver function need to be adequate to tolerate lymphodepleting chemotherapy and manage potential side effects.
  • Performance status — a measure of how well you can carry out daily activities, used as a proxy for overall fitness to tolerate treatment.
  • Active infection or uncontrolled disease — these generally need to be addressed before apheresis and manufacturing can proceed safely.
  • Biomarker confirmation — for example, CLDN18.2 and HER2 status for the gastric cancer indication, or CD19/BCMA expression for blood cancers.

What disqualifies someone (for now)

Common reasons a patient isn't currently a candidate include: a diagnosis that doesn't match any approved indication, insufficient prior treatment (not yet having tried standard options), significant uncontrolled organ dysfunction, or an active uncontrolled infection. In several of these cases, the answer is "not yet" rather than "never" — your reviewing physician will tell you which applies and what, if anything, could change the picture.

How we handle this

Our free medical record review exists specifically to answer this question honestly, against the specific approved criteria for each product, before you spend anything on travel.

Medical disclaimer: CellBridge China is a patient-coordination service and does not provide medical advice, diagnosis or treatment. See our full medical disclaimer.